This trial is active, not recruiting.

Condition alzheimer's disease
Treatments nicotinamide, enduramide placebo
Phase phase 1/phase 2
Sponsor University of California, Irvine
Collaborator Alzheimer's Association
Start date January 2008
End date July 2014
Trial size 50 participants
Trial identifier NCT00580931, IIRG-07-61197


The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Subjects will receive experimental drug in a blinded fashion.
nicotinamide Enduramide
1500 mg twice a day for 6 months
(Placebo Comparator)
Identical in size, shape and color to experimental drug.
enduramide placebo
1 tab twice a day

Primary Outcomes

Alzheimer's Disease Assessment Scale-Cognitive Subscale
time frame: Baseline, 6 wk, 12 wk, 18 wk, 24 wk

Eligibility Criteria

Male or female participants from 50 years up to 95 years old.

Inclusion Criteria: - Diagnosis of probable AD according to DSM-IV criteria - Mild to moderate dementia based on Mini-Mental State Examination [MMSE] score between 13-25 - Minimum age 50 years - Brain imaging (computed tomographic scan or magnetic resonance image) within 12 months consistent with a diagnosis of probable AD - Hachinski Ischemic Score of <4. - Stable doses of concomitant medications, including cholinesterase inhibitors (ChEIs) and/or memantine. Exclusion Criteria: - Dementia due to another cause - Other neurological or psychiatric diseases - Pseudodementia - Unstable medical condition - Initial treatment within 30 days of screening with a ChEI, memantine or any investigational drug - History of alcoholism, drug abuse, liver disease, peptic ulcer disease - Pregnancy, or the potential to become pregnant.

Additional Information

Official title Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease
Principal investigator Steven S Schreiber, MD
Description The goal of this proposal is to show that, nicotinamide (NA), a B3 vitamin, is safe and effective for the treatment of patients with mild to moderate Alzheimer's disease (AD). NA is known to block the ability of certain proteins to regulate other proteins by removing their acetyl groups. Recent evidence has demonstrated that inhibitors such as NA prevent nerve cell degeneration in models of Huntington's disease (HD), Parkinson's disease and Lou Gehrig's disease (or ALS). Despite these beneficial effects in many different animal models, there have been no studies to date using these inhibitors in AD. In some of our recent studies we found that the potent inhibitor, NA, significantly improves learning and memory in transgenic mice that develop AD. NA treatment also resulted in striking changes in tau, a protein that abnormally accumulates in AD. NA has been extensively used in clinical studies over the last 40 years and is generally safe and well-tolerated. As NA is a safe and readily available vitamin supplement, our recent results provide a strong argument for a study of NA in patients with AD. We therefore propose to treat 50 patients with mild to moderate AD with either NA (1500 milligrams twice a day) or an identical but inactive drug (placebo) for 24 weeks. At 6 week intervals we will assess functions such as learning and memory, and ability to carry out daily activities as well as caregiver reports using standardized tests. We will also perform spinal taps at the beginning and end of the study to measure the level of abnormal tau protein in the cerebrospinal fluid. Blood tests will periodically be done to assess liver function and complete blood counts. The results of this study may provide the basis for a more extensive study of NA for the treatment of mild to moderate AD.
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by University of California, Irvine.